XNAS · Healthcare · Biotechnology
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | FY 2025 | — | -7.57 | — | $8.5M | — | +0.25% | +24.83% | +5.69% |
| 2025-12-22 | H1 2025 | — | -11.37 | — | $8,500 | — | — | — | — |
| 2025-04-03 | FY 2024 |
| — |
| -52.80 |
| — |
| $0 |
| — |
| -10.58% |
| -9.09% |
| -9.24% |
| 2024-08-14 | H1 2024 | — | -38.00 | — | $0 | — | +10.37% | -2.31% | +1.42% |
| 2024-03-28 | FY 2023 | — | -232.00 | — | $0 | — | — | — | — |
| 2023-09-28 | H1 2023 | — | -255.00 | — | $0 | — | -4.95% | -22.34% | -77.16% |
Showing last 6 quarters.